Hologic, Inc. (NASDAQ:HOLX) Director Elaine Ullian sold 9,104 shares of the stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $42.40, for a total transaction of $386,009.60. Following the transaction, the director now owns 23,810 shares in the company, valued at $1,009,544. The sale was disclosed in a filing with the SEC, which is available through this link.
Elaine Ullian also recently made the following trade(s):
- On Friday, February 3rd, Elaine Ullian sold 9,423 shares of Hologic stock. The stock was sold at an average price of $39.54, for a total transaction of $372,585.42.
Shares of Hologic, Inc. (NASDAQ:HOLX) traded down 0.28% during trading on Friday, hitting $43.14. 1,035,738 shares of the company traded hands. The stock has a market capitalization of $12.05 billion, a PE ratio of 36.87 and a beta of 1.10. The company has a 50-day moving average of $42.33 and a 200-day moving average of $39.95. Hologic, Inc. has a 52-week low of $32.64 and a 52-week high of $43.30.
Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, February 1st. The medical equipment provider reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.51 by $0.01. The firm had revenue of $734.40 million for the quarter, compared to the consensus estimate of $725.01 million. Hologic had a return on equity of 27.17% and a net margin of 11.57%. The firm’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.46 EPS. Equities analysts expect that Hologic, Inc. will post $1.98 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Hologic, Inc. (HOLX) Director Sells $386,009.60 in Stock” was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.chaffeybreeze.com/2017/04/21/elaine-ullian-sells-9104-shares-of-hologic-inc-holx-stock-updated.html.
A number of hedge funds have recently made changes to their positions in the stock. Global X Management Co. LLC increased its stake in shares of Hologic by 149.9% in the third quarter. Global X Management Co. LLC now owns 3,871 shares of the medical equipment provider’s stock valued at $150,000 after buying an additional 2,322 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Hologic by 159.1% in the third quarter. Tower Research Capital LLC TRC now owns 4,465 shares of the medical equipment provider’s stock worth $173,000 after buying an additional 2,742 shares in the last quarter. Cornercap Investment Counsel Inc. purchased a new stake in Hologic during the fourth quarter worth approximately $202,000. Commerzbank Aktiengesellschaft FI purchased a new stake in Hologic during the fourth quarter worth approximately $207,000. Finally, Boston Advisors LLC purchased a new stake in Hologic during the third quarter worth approximately $202,000. 94.09% of the stock is currently owned by hedge funds and other institutional investors.
A number of analysts have recently weighed in on HOLX shares. Piper Jaffray Companies upgraded shares of Hologic from a “neutral” rating to an “overweight” rating and raised their price target for the company from $44.00 to $48.00 in a report on Wednesday, January 4th. Zacks Investment Research upgraded shares of Hologic from a “sell” rating to a “hold” rating in a report on Friday, February 24th. Evercore ISI cut shares of Hologic from a “buy” rating to a “hold” rating and set a $42.00 price target on the stock. in a report on Wednesday, January 4th. BTIG Research restated a “buy” rating and issued a $47.00 price target on shares of Hologic in a report on Sunday, February 5th. Finally, Bank of America Corp cut shares of Hologic from a “buy” rating to a “neutral” rating in a report on Wednesday, February 15th. Four research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $46.92.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.